Non-specific, rapidly generated cytotoxicity in lymphocytes induced by BCG in vitro: No evidence of enhancing effect from preceding interaction between BCG and transitional cell line cells

Journal of Urology

Volumn 163, Issue 1, 2000, Pages 317-322

  Kaasinen, Eero S ^a   Harju, Leena M ^b   Alfthan, Olof S ^b   Timonen, Tuomo T ^b  

^a Hyvinkään Sairaala   (Finland)

^b NONE

Author keywords

BCG; Mechanism of action; T24

Indexed keywords

BCG VACCINE;

ARTICLE; CELL INTERACTION; CELL KILLING; CELL MEDIATED CYTOTOXICITY; CELL MEDIATED LYMPHOLYSIS; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG MECHANISM; HUMAN; HUMAN CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TUMOR CELL LINE;

EID: 0033992292     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)68045-7     Document Type: Article

References (33)

1. Lamm, D. L.: BCG in Perspective: advances in the treatment nf superficial bladder cancer. Eur Urol, 27(suppl 1): 2, 1995.
2. Bartlett, G. L., Zbar, B. and Rapp, H. J.: Suppression of murine tumor growth by immune reaction to the bacillus Calmette-Guérin strain of mycobacterium bovis. J Nat Cancer Inst, 48: 245, 1972.
3. Zbar, B. and Rapp, H. J.: Immunotherapy of guinea pig cancer with BCG. Cancer, 34: 1532, 1974.
4. Ratliff, T. L., Gillen, D. and Catalona, W. J.: Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol, 137: 155, 1987.
5. El-Demiry, M. I. M., Smith, G., Ritchie, A. W. S., James, K., Cumming, J. A., Hargreave, T. B. and Chisholm, G. D.: Local immune responses after intravesical BCG treatment for carcinoma in situ. Br J Urol, 60: 543, 1987.
6. Böhle A., Gerdes, J., Ulmer, A. J., Hofstetter, A. G. and Flad, H-D.: Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol, 144: 53, 1990.
7. Peuchmaur, M., Benoit, G., Vieillefond, A., Chevalier, A., Lemaigre, G., Martin, E. D. and Jardin, A.: Analysis of mucosal bladder leucocyte subpopulations in patients treated with intravesical bacillus Calmette-Guerin. Urol Res, 17: 299, 1989.
8. De Boer, E. C., De Jong, W. H., van der Meijden, A. P. M., Steerenberg, P. A., Witjes, J. A., Vegt, P. D. J., Debruyne, F. M. J. and Ruitenberg, E. J.: Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin. Cancer Immunol Immunother, 33: 411, 1991.
9. Ratliff, T. L., Haaff, E. O. and Catalona, W. J.: Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer. Clin Immunol Immunopath, 40: 375, 1986.
10. Prescott, S., James, K., Hargreave, T. B., Chisholm, G. D. and Smyth, J. F.: Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol, 144: 1248, 1990.
11. Jackson, A. M., Prescott, S., Hawkyard, S. J., James, K. and Chisholm, G.: The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical evans BCG therapy. Cancer Immunol Immunother, 36: 25, 1993.
12. Esuvaranathan, K., Alexandroff, A. B., McIntyre, M., Jackson, A. M., Prescott, S., Chisholm, G. D. and James, K.: Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. J Urol, 154: 572, 1995.
13. Mizutani, Y., Nio, Y., Fukumoto, M. and Yoshida, O.: Effects of bacillus Calmette-Guerin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients with urinary bladder cancer. Cancer, 69: 537, 1992.
14. Kuroda, K., Brown, E. J., Telle, W. B., Russell, D. G. and Ratliff, T. L.: Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells. J Clin Invest, 91: 69, 1993.
15. Cheng, D. L-W., Shu, W-P., Choi, J. C. S., Margolis, E. J., Droller, M. J. and Liu, B. C-S.: Bacillus Calmette-Guérin interacts with the carboxyl-terminal heparin binding domain of fibronectin: implications for BCG-mediated antitumor activity. J Urol, 152: 1275, 1994.
16. Becich, M. J., Carroll, S. and Ratliff, T. L.: Internalization of bacille Calmette-Guerin by bladder tumor cells. J Urol, 145: 1316, 1991.
17. Teppema, J. S., de Boer, E. C., Steerenberg, P. A. and van der Meijden, A. P. M.: Morphological aspects of the interaction of bacillus Calmette-Guerin with urothelial bladder cells in vivo and in vitro: relevance for antitumor activity? Urol Res, 20: 219, 1992.
18. Mandeville, R., Sombo, F-M. and Rocheleau, N.: Natural cell-mediated cytotoxicity in normal human peripheral blood lymphocytes and its in vitro boosting with BCG. Cancer Immunol Immunother, 15: 17, 1983.
19. Pryor, K., Goddard, J., Goldstein, D., Stricker, P., Russel, P., Golovsky, D. and Penny, R.: Bacillus Calmette-Guerin (BCG) enhances monocyte-and lymphocyte-mediated bladder tumour cell killing. Br J Cancer, 71: 801, 1995.
20. Böhle, A., Thanhäuser A., Ulmer, A. J., Ernst, M., Flad, H-D. and Jocham, D.: Dissecting the immunobiological effects of bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon. J Urol, 150: 1932, 1993.
21. Böhle, A., Thanhäuser A., Ulmer, A. J., Mattern, T., Ernst, M., Flad, H-D. and Jocham, D.: On the mode of action of intravesical bacillus Calmette-Guérin: in vitro characterization of BCG-activated killer cells. Urol Res, 22: 185, 1994.
22. Thanhäuser, A., Böhle, A., Schneider, B., Reiling, N., Mattern, T., Ernst, M., Flad, H-D. and Ulmer, A. J.: The induction of bacillus-Calmette-Guérin-activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol Immunother, 40: 103, 1995.
23. Turner, J. and Dockrell, H. M.: Stimulation of human peripheral blood mononuclear cells with live Mycobacterium bovis BCG activates cytolytic CD8+ T cells in vitro. Immunology, 87: 339, 1996.
24. Koga, S., Kiyohara, T., Taniguchi, K., Nishikido, M., Kubota, S., Sakuragi, T., Shindo, K. and Saitoh, Y.: BCG induced killer cell activity. Urol Res, 16: 351, 1988.
25. Pang, A. S. D. and Morales, A.: BCG induced murine peritoneal exudate cells: Cytotoxic activity against a syngeneic bladder tumor cell line. J Urol, 127: 1225, 1982.
26. Kurisu, H., Matsuyama, H., Ohmoto, Y., Shimabukuro, T. and Naito, K.: Cytokine-mediated antitumor effect of bacillus Calmette-Guérin on tumor cells in vitro. Cancer Immunol Immunother, 39: 249, 1994.
27. Böyum, A.: Isolation of mononuclear cells and granulocytes from human blood. Scand. J Clin Invest, 97 (Suppl. 21): 77, 1988.
28. Mizutani, Y. and Yoshida, O.: In vitro enhancement of natural killer cell activity by BCG and the antagonistic inhibition of the susceptibility of K562 cells to lysis by peripheral blood lymphocytes in patients with urinary bladder tumor. Int J Urol, 1: 49, 1994.
29. Bloomberg, S. D., Brosman, S. A., Hausman, M. S., Cohen, A. and Battenberg, J. D.: The effects of BCG on the dog bladder. Invest Urol, 12: 423, 1975.
30. Matsumoto, H., Suzuki, K., Tsuyuguchi, K., Tanaka, E., Amitani, R., Maeda, A., Yamamoto, K., Sasada, M. and Kuze, F.: Interleukin-12 gene expression in human monocyte-derived macrophages stimulated with Mycobacterium bovis BCG: cytokine regulation and effect of NK cells. Infect Immun, 65: 4405, 1997.
31. Kaasinen, E. S., Kalliomäki, P. H. W., Alfthan, O. S. and Timonen, T. T.: Bacillus Calmette-Guérin sensitises fresh transitional carcinoma cells and T24 cell line to non-MHC-restricted cytotoxicity in vitro. Br J Urol, 72: 897, 1993.
32. Den Otter, W., Dobrowolski, Z., Bugajski, A., Papla, B., van der Meijden, A. P. M., Koten, J. W., Boon, T. A., Siedlar, M. and Zembala, M.: Intravesical interleukin-2 in T1 papillary bladder carcinoma: Regression of marker lesion in 8 of 10 patients. J Urol, 159: 1183, 1998.
33. Huland, E. and Huland, H.: Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res, 49: 5469, 1989.